Kanyi Maqubela

Who they are

Kanyi Maqubela is Managing Partner at Kindred Ventures — co-founded Heartbeat Health, now the largest virtual heart health platform in the U.S., and littleBits, the electronic building-blocks company later acquired by Sphero.

Person

Kanyi studied Philosophy at Stanford — a degree that signals the kind of first-principles thinking that shows up throughout his career. He came up through the Obama 2008 campaign as a worker, then moved into early tech roles at Doostang and One Block Off the Grid, before a stint as VP of Marketing and eventually as an Adjunct Professor at NYU Tisch School of the Arts. His VC formation happened at Collaborative Fund, where he made partner before co-founding Kindred Ventures in 2014 with Steve Jang. Alongside the investor track, he co-founded three companies: Heartbeat Health (the largest virtual heart health platform in the U.S.), littleBits (electronic building blocks to democratize invention, later acquired by Sphero), and Primary Venture Partners (an early-stage VC firm based in New York). He writes at kanyi.blog — active since 2008, covering VC, entrepreneurship, identity, infographics, photography, and the implications of artificial general intelligence — and has published essays in The Atlantic and at TechCrunch. The through-line is someone who moves between building, backing, and writing about systems that change who gets access to technology.

Company

Kindred Ventures made its biggest capital statement to date in June 2026, closing $355 million across two vehicles — Kindred Ventures IV (early-stage) and Kindred Selector II (early-growth) — framing the raise explicitly around the 'age of intelligence.' The firm has been deploying actively: in August 2026 it led the $25 million seed round for Bios Life, a personalized cancer surveillance startup, and participated in a $23 million Series A for Sandbar, an AI-powered voice ring startup. In July 2026 it backed Assured, a healthcare AI agentic platform, in its Series A. The portfolio thesis centers on AI-native consumer and enterprise experiences, physical AI, compute, infrastructure, energy, science, and space — with prior bets on Perplexity, Fal, Nuro, Inversion Space, and Aalo Atomics. The firm manages $600 million AUM as of 2026 and has produced 13 unicorns, 5 IPOs, and 25 acquisitions across its portfolio history.

Market

Kindred operates in the seed and pre-seed VC market, where capital is increasingly concentrated around a small set of high-profile AI startups, compressing access for the broader ecosystem. The firm's concentrated frontier strategy — AI, compute, energy, space — puts it in direct competition with other early-stage funds chasing the same deals, though its early Uber, Coinbase, and Postmates track record gives it sourcing credibility. Valuation corrections and down rounds have characterized late 2024 and 2025, making the $355 million raise and active August 2026 deal flow a signal that Kindred is leaning in rather than waiting out the cycle.

Network

Kanyi's most anchored professional relationship is with Steve Jang, Kindred's founder and co-Managing Partner — they've run the firm together since its 2014 founding. At Startup Grind 2025 he shared a panel on AI in healthcare with Othman Laraki, and he holds a board observer seat at Tala.

Steve Jang· Founder and co-Managing Partner, Kindred Ventures
Othman Laraki· Co-panelist, Startup Grind 2025 (AI in Healthcare)

How they likely show up

Hybrid role pattern (investor + operator + founder) → doesn't separate 'thinking about' a problem from 'building toward' it; likely engages with operational detail even in a GP seat.
Co-founded Heartbeat Health while running a VC firm → high tolerance for parallel workstreams; probably expects the same bias toward action from founders he backs.
Philosophy degree at Stanford + writing at kanyi.blog since 2008 → first-principles thinker who works things out in writing; likely responds well to structured conceptual framing, not just data drops.
Active across multiple podcast formats (20VC, Invest Like the Best, Consumer VC, Origins) → comfortable being on record with opinions; not a behind-the-scenes operator.
Adjunct Professor at NYU Tisch + essays in The Atlantic → thinks about audiences beyond the tech bubble; probably finds purely inside-baseball VC conversation limiting.
Spoke at ViVe 2026 on specialty care and Startup Grind 2025 on AI in healthcare → healthcare AI is a current live thesis, not historical interest; questions in this space will land.

Conversation tips

→ Reference a specific post from kanyi.blog or his Atlantic essays — he's been writing since 2008 and the topics range widely; showing you've read him specifically (not just that he 'writes') will register.
→ Ask about the Heartbeat Health origin story — he built it while investing, which is unusual; the tension between investor conviction and founder commitment is a real story there.
→ Don't pitch him on a company without a clear view on why it's a frontier bet — his fund thesis is explicitly 'age of intelligence,' and incremental SaaS won't track for him.
→ He appeared on the Good Work Show episode titled 'Beyond Unicorns: Identity, Innovation, and the Future of Venture Capital' — that framing ('beyond unicorns') hints at a broader view of what VC should do; worth engaging with that tension rather than leading with pure return metrics.

Toolbox

Openers

Open on the Bios Life seed lead in August 2026 — Kindred led a $25 million round for a personalized cancer surveillance startup, a pointed healthcare AI bet that connects directly to his Heartbeat Health founding history.
Mention kanyi.blog — his personal site, active since 2008, covers AGI implications alongside photography and infographics; it's a rare combo that signals how he thinks, and most people meeting him won't have read it.
Reference the $355 million Fund IV / Selector II close in June 2026 and its explicit 'age of intelligence' framing — it's his firm's biggest capital moment and the thesis is specific enough to have a real conversation about what bets it enables.

Discovery questions

You co-founded Heartbeat Health while running Kindred — at what point did the investor conviction become 'I need to build this myself,' and how did you manage the conflict?
The Selector II vehicle pairs early-growth capital alongside seed — how does having both change how you think about entry points and follow-on discipline?
Your ViVe 2026 panel was on supercharging specialty care — where do you see the biggest gap between what AI can do in cardiology today and what the market is actually willing to pay for?

Avoid

Don't lead with generic 'AI is transforming healthcare' framing — he's been investing in digital health since before that was consensus, spoke at Startup Grind 2025 and ViVe 2026 on the specific contours of AI in care, and co-founded a cardiology platform; he'll want specifics, not the category pitch.

Make it yours